How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

68,113 results for

Neurology Links

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Reduction of Movement in Neurological Diseases: Effects on Neural Stem Cells Characteristics Full Text available with Trip Pro

animals present an incomplete differentiation/maturation. The overall results support the existence of a link between reduction of exercise and muscle disuse and metabolism in the brain and thus represent valuable new information that could clarify how circumstances such as the absence of load and the lack of movement that occurs in people with some neurological diseases, may affect the properties of NSCs and contribute to the negative manifestations of these conditions. (...) Reduction of Movement in Neurological Diseases: Effects on Neural Stem Cells Characteristics Both astronauts and patients affected by chronic movement-limiting pathologies face impairment in muscle and/or brain performance. Increased patient survival expectations and the expected longer stays in space by astronauts may result in prolonged motor deprivation and consequent pathological effects. Severe movement limitation can influence not only the motor and metabolic systems but also the nervous

2018 Frontiers in neuroscience

82. Evaluating the Utility of a Structured Clinical Protocol for Reducing the Impact of Behavioural and Psychological Symptoms of Dementia in Progressive Neurological Diseases: A Pilot Study Full Text available with Trip Pro

Evaluating the Utility of a Structured Clinical Protocol for Reducing the Impact of Behavioural and Psychological Symptoms of Dementia in Progressive Neurological Diseases: A Pilot Study Behavioural and psychological symptoms of dementia (BPSD) cause significant distress to both aged care residents and staff. Despite the high prevalence of BPSD in progressive neurological diseases (PNDs) such as multiple sclerosis, Huntington's disease, and Parkinson's disease, the utility of a structured (...) alongside a statistically significant decrease in BPSD from T1 to T2. In RAC, there was no significant time effect for BPSD or staff coping; however, a medium effect size was observed for staff job stress.Staff training and clinical support in the use of a structured clinical protocol for managing BPSD were linked to reductions in staff job stress, which may in turn increase staff capacity to identify indicators of resident distress and respond accordingly. Site variation in outcomes may relate

2018 Behavioural neurology

83. mRNA Translation Gone Awry: Translation Fidelity and Neurological Disease. Full Text available with Trip Pro

neurological disorders that are linked to errors in tRNA aminoacylation and ribosome decoding. We draw on studies from genetic models, including yeast and mice, to enhance our understanding of the translational defects observed in these diseases. Finally, we emphasize the importance of tRNA, their associated enzymes, and the inextricable link between accuracy and efficiency in the maintenance of translational fidelity.Copyright © 2017 Elsevier Ltd. All rights reserved. (...) mRNA Translation Gone Awry: Translation Fidelity and Neurological Disease. Errors during mRNA translation can lead to a reduction in the levels of functional proteins and an increase in deleterious molecules. Advances in next-generation sequencing have led to the discovery of rare genetic disorders, many caused by mutations in genes encoding the mRNA translation machinery, as well as to a better understanding of translational dynamics through ribosome profiling. We discuss here multiple

2018 Trends in Genetics

84. Normalization of Soluble CD163 after Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. Full Text available with Trip Pro

Normalization of Soluble CD163 after Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. Myeloid activation contributes to cognitive impairment in chronic human immunodeficiency virus (HIV) infection. We explored whether combination antiretroviral therapy (cART) initiation during acute HIV infection impacts CD163 shedding, a myeloid activation marker, and in turn, implications on the central nervous system (CNS).We measured soluble (...) CD163 (sCD163) levels in plasma and cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay in Thais who initiated cART during acute HIV infection (Fiebig stages I-IV). Examination of CNS involvement included neuropsychological testing and analysis of brain metabolites by magnetic resonance spectroscopy. Chronic HIV-infected or uninfected Thais served as controls.We examined 51 adults with acute HIV infection (Fiebig stages I-III; male sex, >90%; age, 31 years). sCD163 levels before and after

2018 Journal of Infectious Diseases

85. Do Headache Patients Require More Care in Between Visits Than Other Neurology Outpatients? (Abstract)

clinics.Patients in a headache clinic in an academic tertiary care setting require a high intensity of remote outpatient care, more so than patients in other neurology subspecialty clinics and general neurology clinic, with the exception of the neuroimmunology/MS clinic. This is to a large extent secondary to the very frequent use of secure email linked to the electronic medical record by headache patients.© 2018 American Headache Society. (...) Do Headache Patients Require More Care in Between Visits Than Other Neurology Outpatients? There is evidence that time spent in patient care in between patient visits is increasing and a contributor to physician burnout. The extent of this work on providers in the field of headache medicine is unknown.To establish whether headache outpatients require a high level of care in addition to clinic visits, based on the quantity of remote encounters per patient (phone calls and secure email

2018 Headache

86. Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. Full Text available with Trip Pro

Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. OBJECTIVEDelayed ischemic neurological deficit (DIND) is a leading cause of mortality and morbidity after aneurysmal subarachnoid hemorrhage (aSAH). Arginine vasopressin (AVP) is a hormone released by the posterior pituitary. It is known to cause cerebral vasoconstriction and has been implicated in hyponatremia secondary (...) to the syndrome of inappropriate antidiuretic hormone secretion. Direct measurement of AVP is limited by its short half-life. Copeptin, a cleavage product of the AVP precursor protein, was therefore used as a surrogate marker for AVP. This study aimed to investigate the temporal relationship between changes in copeptin concentrations and episodes of DIND and hyponatremia.METHODSCopeptin concentrations in cerebrospinal fluid were quantified using enzyme-linked immunosorbent assay in 19 patients: 10 patients

2018 Journal of Neurosurgery

87. Low Serum Kallistatin Level was Associated with Poor Neurological Outcome of Out-of-Hospital Cardiac Arrest Survivors: Proteomics study. (Abstract)

Low Serum Kallistatin Level was Associated with Poor Neurological Outcome of Out-of-Hospital Cardiac Arrest Survivors: Proteomics study. To identify proteins of which depletion are associated with the poor 6-month neurological outcome of out-of-hospital cardiac arrest survivors.Seven healthy volunteers and 34 out-of-hospital cardiac arrest survivors admitted to the intensive care unit (ICU) and underwent targeted-temperature management were enrolled. According to the 6-month cerebral (...) and poor outcome groups (>2-fold change) and excluded 5 proteins related to haemolysis or remaining high abundant proteins. To confirm the 2 identified proteins: retinal dehydrogenase 1 and Kallistatin, we performed enzyme-linked immunosorbent assay with individual serum. Finally, old age (odds ratio = 1.055; 95% confidence interval, 1.002-1.112; p = 0.043) and low serum kallistatin level at 0 h (odds ratio = 0.784; 95% confidence interval, 0.618-0.995; p = 0.046) were independently associated

2018 Resuscitation

88. Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children

-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children Estimated Study Start Date : October 30, 2019 Estimated Primary Completion Date : October 30, 2021 Estimated Study Completion Date : December 30, 2021 Resource links provided by the National Library of Medicine related topics: related topics: resources: Groups and Cohorts Go to Group/Cohort 1 spinal muscular atrophy, SMA Progressive muscular atrophy (SMA) is a group of autosomal recessive (...) adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive

2018 Clinical Trials

89. Synek Score to Predict Poor Neurological Outcome Post Resuscitated Cardiac Arrest

Enrollment : 240 participants Observational Model: Cohort Time Perspective: Retrospective Official Title: The Performance of the Synek Score to Predict Poor Neurological Outcome in Postanoxic Comatose Patients Treated With Induced Hypothermia Actual Study Start Date : November 1, 2013 Actual Primary Completion Date : November 1, 2017 Actual Study Completion Date : November 1, 2017 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome Measures Go (...) Synek Score to Predict Poor Neurological Outcome Post Resuscitated Cardiac Arrest Synek Score to Predict Poor Neurological Outcome Post Resuscitated Cardiac Arrest - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2018 Clinical Trials

90. The glymphatic pathway in neurological disorders. Full Text available with Trip Pro

The glymphatic pathway in neurological disorders. The glymphatic (glial-lymphatic) pathway is a fluid-clearance pathway identified in the rodent brain in 2012. This pathway subserves the flow of CSF into the brain along arterial perivascular spaces and subsequently into the brain interstitium, facilitated by aquaporin 4 (AQP4) water channels. The pathway then directs flow towards the venous perivascular and perineuronal spaces, ultimately clearing solutes from the neuropil into meningeal (...) evident in brain tissue from patients with Alzheimer's disease or normal pressure hydrocephalus; glymphatic MRI scans of patients with normal pressure hydrocephalus show reduced CSF tracer entry and clearance. WHERE NEXT?: Research is needed to confirm whether specific factors driving glymphatic flow in rodents also apply to humans. Longitudinal imaging studies evaluating human CSF dynamics will determine whether a causal link exists between reduced brain solute clearance and the development

2018 Lancet Neurology

91. Low frequency pulsed electromagnetic field promotes the recovery of neurological function after spinal cord injury in rats. Full Text available with Trip Pro

Low frequency pulsed electromagnetic field promotes the recovery of neurological function after spinal cord injury in rats. Low frequency pulsed electromagnetic field (LFPEMF) has been shown to provide anti-inflammatory and antioxidative effects. However, there are no reports on whether LFPEMF can treat spinal cord injury (SCI) and its therapeutic mechanism. Therefore, this study was conducted to investigate whether LFPEMF can promote the recovery of neurological function after SCI in rats (...) and its therapeutic mechanism. Basso-Beattie-Bresnahan (BBB) score and transcranial magnetic motor-evoked potentials (tcMMEPs) were recorded to assess the recovery of neurological function. Hematoxylin and eosin (HE) staining and luxol fast blue (LFB) staining were performed to assess the severity of SCI. Immunofluorescence (IF) staining and western blotting (WB) were performed to assess the differentiation of oligodendrocyte precursor cells (OPCs) into oligodendrocytes (OLs). Toluidine blue (TB

2018 Journal of Orthopaedic Research

92. Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders

Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders (SECAMS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

93. Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

94. A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients

A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

95. Reliability of Hammersmith Examination in Prediction of Neurological Outcomes (REHAPENO)

(developmental milestones). Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 50 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Reliability of Hammersmith Examination in Prediction of Neurological Outcomes In Preterm Infants - Observational Study (REHAPENO) Actual Study Start Date : March 1, 2018 Actual Primary Completion Date : January 25, 2019 Actual Study Completion Date : January 25, 2019 Resource links provided (...) Reliability of Hammersmith Examination in Prediction of Neurological Outcomes (REHAPENO) Reliability of Hammersmith Examination in Prediction of Neurological Outcomes (REHAPENO) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2018 Clinical Trials

96. Caffeine and Neurologic Recovery Following Surgery and General Anesthesia

controlled trial at the University of Michigan Health System. Primary Purpose: Treatment Official Title: Caffeine and Neurologic Recovery Following Surgery and General Anesthesia Actual Study Start Date : July 10, 2018 Estimated Primary Completion Date : June 11, 2020 Estimated Study Completion Date : July 11, 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Experimental Prepared (...) Caffeine and Neurologic Recovery Following Surgery and General Anesthesia Caffeine and Neurologic Recovery Following Surgery and General Anesthesia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Caffeine

2018 Clinical Trials

97. Preventing Falls and Participation Restrictions in Neurological Diseases

Restrictions in Subjects With Neurological Diseases Actual Study Start Date : January 1, 2015 Actual Primary Completion Date : December 30, 2016 Actual Study Completion Date : January 15, 2017 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Experimental group: Education group Participants in the experimental intervention group (education group) received an educational program and tailored home (...) Preventing Falls and Participation Restrictions in Neurological Diseases Preventing Falls and Participation Restrictions in Neurological Diseases - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Preventing

2018 Clinical Trials

98. Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment

: Observational Actual Enrollment : 70 participants Observational Model: Case-Only Time Perspective: Retrospective Official Title: Neo-adjuvant Treatment of Glioblastomas With Marked to Severe Neurological Impairment Using Upfront Bevacizumab/témozolomide Association Before an Eventual Radiotherapy. Multicentric Phase II Study Actual Study Start Date : January 1, 2011 Actual Primary Completion Date : May 12, 2017 Actual Study Completion Date : May 12, 2017 Resource links provided by the National Library (...) Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2018 Clinical Trials

99. Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders

Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03606668 Recruitment Status

2018 Clinical Trials

100. Multimodal Assessment of the Neurological Prognosis of Patients With Brain Lesions on ExtraCorporeal Life Support

Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Intervention Details: Other: clinical examinations Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery: right and left pupillometry (3 times) BIS values right and left NIRS values right and left transcranial Doppler neurological clinical (...) Multimodal Assessment of the Neurological Prognosis of Patients With Brain Lesions on ExtraCorporeal Life Support Multimodal Assessment of the Neurological Prognosis of Patients With Brain Lesions on ExtraCorporeal Life Support - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>